Reverse Payment Settlements—Economic Issues Arising in Antitrust Litigation


The pharmaceutical industry has reportedly reduced its use of anticompetitive agreements after challenges to reverse payment settlement have been renewed since Actavis. Although this trend will push forward as parties involved in reverse payment settlements face litigation threats, new and ongoing litigation is expected to surface in relation to pre-Actavis settlement agreements.

In this webcast, Edgeworth Principal Consultant Dr. David Colino will join a panel of thought leaders and practitioners to discuss the current trends and issues in reverse payment settlements. The speakers will share their insights on the implications of recent cases and will discuss key economic issues upon which the outcomes of antitrust litigation can turn. 

Edgeworth’s complimentary passes are available for the first 30 registrants.

Related Materials

Jump to Page

This website uses cookies to improve functionality and performance. By continuing to use this website, you agree to the use of cookies in accordance with our Privacy Policy.  If you are a California resident, read our California Information Practices.